Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/46293
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKarimnia N.-
dc.contributor.authorWilson A.L.-
dc.contributor.authorGreen E.-
dc.contributor.authorMatthews A.-
dc.contributor.authorJobling T.W.-
dc.contributor.authorPlebanski M.-
dc.contributor.authorBilandzic M.-
dc.contributor.authorStephens A.N.-
dc.date.accessioned2022-02-10T23:55:53Z-
dc.date.available2022-02-10T23:55:53Z-
dc.date.copyright2021-
dc.date.issued2021-09-10en
dc.identifier.citationJournal of Experimental and Clinical Cancer Research. 40(1) (no pagination), 2021. Article Number: 276. Date of Publication: December 2021.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/46293-
dc.description.abstractBackground: Leader cells are a subset of cancer cells that coordinate the complex cell-cell and cell-matrix interactions required for ovarian cancer migration, invasion, tumour deposition and are negatively associated with progression-free survival and response to therapy. Emerging evidence suggests leader cells may be enriched in response to chemotherapy, underlying disease recurrence following treatment. Method(s): CRISPR was used to insert a bicistronic T2A-GFP cassette under the native KRT14 (leader cell) promoter. 2D and 3D drug screens were completed in the presence of chemotherapies used in ovarian cancer management. Leader cell; proliferative (Ki67); and apoptotic status (Cleaved Caspase 3) were defined by live cell imaging and flow cytometry. Quantitative real-time PCR defined "stemness" profiles. Proliferation was assessed on the xCELLigence real time cell analyser. Statistical Analysis was performed using unpaired non-parametric t-tests or one-way ANOVA and Tukey's multiple comparison post hoc. Result(s): Leader cells represent a transcriptionally plastic subpopulation of ovarian cancer cells that arise independently of cell division or DNA replication, and exhibit a "stemness" profile that does not correlate with epithelial-to-mesenchymal transition. Chemotherapeutics increased apoptosis-resistant leader cells in vitro, who retained motility and expressed known chemo-resistance markers including ALDH1, Twist and CD44v6. Functional impairment of leader cells restored chemosensitivity, with leader cell-deficient lines failing to recover following chemotherapeutic intervention. Conclusion(s): Our data demonstrate that ovarian cancer leader cells are resistant to a diverse array of chemotherapeutic agents, and are likely to play a critical role in the recurrence of chemo-resistant disease as drivers of poor treatment outcomes.Copyright © 2021, The Author(s).-
dc.publisherBioMed Central Ltd-
dc.relation.ispartofJournal of Experimental and Clinical Cancer Research-
dc.subject.meshanalysis of variance-
dc.subject.meshapoptosis-
dc.subject.mesh*cancer cell-
dc.subject.meshcancer recurrence-
dc.subject.meshcancer stem cell-
dc.subject.meshcell division-
dc.subject.meshcell motility-
dc.subject.meshcell proliferation-
dc.subject.meshcell selection-
dc.subject.meshcell subpopulation-
dc.subject.meshcell viability-
dc.subject.meshchemosensitivity-
dc.subject.meshclustered regularly interspaced short palindromic repeat-
dc.subject.meshcorrelation analysis-
dc.subject.meshDNA replication-
dc.subject.meshdrug screening-
dc.subject.meshenzyme degradation-
dc.subject.meshepithelial mesenchymal transition-
dc.subject.meshflow cytometry-
dc.subject.meshIC50-
dc.subject.meshin vitro study-
dc.subject.meshlive cell imaging-
dc.subject.meshnonparametric test-
dc.subject.mesh*ovary cancer/dr [Drug Resistance]-
dc.subject.meshpost hoc analysis-
dc.subject.meshpromoter region-
dc.subject.meshprotein expression-
dc.subject.meshreal time polymerase chain reaction-
dc.subject.meshtreatment outcome-
dc.subject.meshaldehyde dehydrogenase isoenzyme 1/ec [Endogenous Compound]-
dc.subject.mesh*antineoplastic agent-
dc.subject.meshcarboplatin/pd [Pharmacology]-
dc.subject.meshcaspase 3/ec [Endogenous Compound]-
dc.subject.meshCD133 antigen/ec [Endogenous Compound]-
dc.subject.meshCD44v6 antigen/ec [Endogenous Compound]-
dc.subject.meshcisplatin/pd [Pharmacology]-
dc.subject.meshcyclophosphamide/pd [Pharmacology]-
dc.subject.meshcytokeratin 14/ec [Endogenous Compound]-
dc.subject.meshDNA/ec [Endogenous Compound]-
dc.subject.meshdoxorubicin/pd [Pharmacology]-
dc.subject.meshepithelial cell adhesion molecule/ec [Endogenous Compound]-
dc.subject.meshfibronectin/ec [Endogenous Compound]-
dc.subject.meshgreen fluorescent protein-
dc.subject.meshKi 67 antigen/ec [Endogenous Compound]-
dc.subject.meshnerve cell adhesion molecule/ec [Endogenous Compound]-
dc.subject.meshNotch receptor/ec [Endogenous Compound]-
dc.subject.meshoctamer transcription factor 4/ec [Endogenous Compound]-
dc.subject.mesholaparib/pd [Pharmacology]-
dc.subject.meshpaclitaxel/pd [Pharmacology]-
dc.subject.meshrucaparib/pd [Pharmacology]-
dc.subject.meshstem cell factor receptor/ec [Endogenous Compound]-
dc.subject.meshtopotecan/pd [Pharmacology]-
dc.subject.meshtranscription factor NANOG/ec [Endogenous Compound]-
dc.subject.meshtranscription factor Slug/ec [Endogenous Compound]-
dc.subject.meshtranscription factor Snail/ec [Endogenous Compound]-
dc.subject.meshtranscription factor Twist/ec [Endogenous Compound]-
dc.subject.meshuvomorulin/ec [Endogenous Compound]-
dc.subject.meshvimentin/ec [Endogenous Compound]-
dc.subject.meshWnt1 protein/ec [Endogenous Compound]-
dc.subject.mesh*leader cell-
dc.titleChemoresistance is mediated by ovarian cancer leader cells in vitro.-
dc.typeArticle-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1186/s13046-021-02086-3-
dc.publisher.placeUnited Kingdom-
dc.identifier.pubmedid34470672 [http://www.ncbi.nlm.nih.gov/pubmed/?term=34470672]-
dc.identifier.institution(Jobling) Monash Medical Centre, Department of Gynaecology Oncology, Monash Health, Moorabbin, Australiaen
dc.identifier.institution(Karimnia, Wilson, Green, Matthews, Bilandzic, Stephens) Hudson Institute of Medical Research, 27-31 Wright St, Clayton, VIC 3168, Australiaen
dc.identifier.institution(Green, Matthews) Department of Molecular and Translational Sciences, Monash University, Clayton, Australiaen
dc.identifier.institution(Plebanski) School of Health and Biomedical Sciences, RMIT University, Bundoora, Australiaen
dc.subect.keywordsarticle-
dc.subect.keywordscontrolled study-
dc.subect.keywordshuman-
dc.subect.keywordshuman cell-
dc.subect.keywordshuman tissue-
dc.identifier.affiliationext(Karimnia, Wilson, Green, Matthews, Bilandzic, Stephens) Hudson Institute of Medical Research, 27-31 Wright St, Clayton, VIC 3168, Australia-
dc.identifier.affiliationext(Green, Matthews) Department of Molecular and Translational Sciences, Monash University, Clayton, Australia-
dc.identifier.affiliationext(Plebanski) School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia-
dc.identifier.affiliationmh(Jobling) Monash Medical Centre, Department of Gynaecology Oncology, Monash Health, Moorabbin, Australia-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeArticle-
item.cerifentitytypePublications-
crisitem.author.deptObstetrics and Gynaecology (Monash Women's)-
Appears in Collections:Articles
Show simple item record

Page view(s)

8
checked on Nov 24, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.